Trimethaphan

Trimethaphan

Clinical data
Routes of administration	Oral, IM, IV
ATC code	C02BA01 (WHO)
Identifiers
IUPAC name decahydro-2-oxo-1,3-bis(phenylmethyl)- thieno(1',2':1,2)thieno(3,4-d)imidazol-5-ium
CAS Number	7187-66-8
PubChem CID	23576
DrugBank	APRD00044
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H25N2OS
Molar mass	365.513 g/mol

WikiDoc Resources for Trimethaphan
Articles
Most recent articles on Trimethaphan Most cited articles on Trimethaphan Review articles on Trimethaphan Articles on Trimethaphan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trimethaphan Images of Trimethaphan Photos of Trimethaphan Podcasts & MP3s on Trimethaphan Videos on Trimethaphan
Evidence Based Medicine
Cochrane Collaboration on Trimethaphan Bandolier on Trimethaphan TRIP on Trimethaphan
Clinical Trials
Ongoing Trials on Trimethaphan at Clinical Trials.gov Trial results on Trimethaphan Clinical Trials on Trimethaphan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trimethaphan NICE Guidance on Trimethaphan NHS PRODIGY Guidance FDA on Trimethaphan CDC on Trimethaphan
Books
Books on Trimethaphan
News
Trimethaphan in the news Be alerted to news on Trimethaphan News trends on Trimethaphan
Commentary
Blogs on Trimethaphan
Definitions
Definitions of Trimethaphan
Patient Resources / Community
Patient resources on Trimethaphan Discussion groups on Trimethaphan Patient Handouts on Trimethaphan Directions to Hospitals Treating Trimethaphan Risk calculators and risk factors for Trimethaphan
Healthcare Provider Resources
Symptoms of Trimethaphan Causes & Risk Factors for Trimethaphan Diagnostic studies for Trimethaphan Treatment of Trimethaphan
Continuing Medical Education (CME)
CME Programs on Trimethaphan
International
Trimethaphan en Espanol Trimethaphan en Francais
Business
Trimethaphan in the Marketplace Patents on Trimethaphan
Experimental / Informatics
List of terms related to Trimethaphan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trimethaphan is a drug that counteracts cholinergic transmission at the nicotinic receptors of the autonomic ganglia and therefore blocks both the sympathetic nervous system and the parasympathetic nervous system. It acts as a non-depolarizing competitive antagonist at the nicotinic acetylcholine receptor, is short-acting, and is given intravenously.

Effects

Trimethaphan is a quaternary amine and therefore carries a positive charge. Being charged, it cannot cross lipid cell membranes, such as those that comprise the blood-brain barrier. Due to this, trimethaphan does not have any effect on the central nervous system.

The ciliary muscle of the eye functions to round the lens for accommodation and is controlled mainly by parasympathetic system input. With administration of a ganglion-blocking drug, the ciliary muscle cannot contract (cycloplegia) and the patient loses the ability to focus their eyes.

Trimethaphan has a strong effect on the cardiovascular system. The size of blood vessels is primarily controlled by the sympathetic nervous system. Loss of sympathetic system input to the blood vessels causes them to get larger (vasodilation) which has the effect of lowering blood pressure. Postural hypotension is a common side effect of such drugs. Effects on the heart include a decreased force of contraction and an increase in heart rate (tachycardia). Although it is important to note that this reflexive tachycardia can be diminished or undetected due to the fact that Trimethaphan is also blocking the sympathetic ganglia innervating the heart.

The motility of the gastrointestinal tract is regulated by the parasympathetic system, and blockage of this input results in diminished motility and constipation.

Therapeutic Uses

The therapeutic uses of trimethaphan are very limited due to the competition from newer drugs that are more selective in their actions and effects produced. It is occasionally used to treat a hypertensive crisis and dissecting aortic aneurysm, to treat pulmonary edema, and to reduce bleeding during neurosurgery.

Adverse Effects

The adverse effects are due to its nonselective ganglion block and are described in the "Effects" section above. The side effects are severe enough to limit this drugs use to emergency and acute situations.

References

• "Ganglion-blocking Drugs." Drug Benefits and Risks: International Textbook of Clinical Pharmacology. (2001). ISBN 0-471-89927-5
• Katzung, Bertram G. Basic and Clinical Pharmacology, 9th ed. (2004). ISBN 0-07-141092-9